GALECTIN THERAPEUTICS INC 8K

Galectin Therapeutics reported Q2 2026 financial results and a major balance sheet strengthening via conversion of about $105.8 million of insider debt to equity, alongside regulatory progress toward a Phase 3 trial of belapectin in MASH cirrhosis.

On August 14, 2026, Galectin Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update, highlighting FDA alignment on key design elements for a planned registrational Phase 3 trial of its lead drug belapectin in MASH cirrhosis with portal hypertension, multiple scientific presentations and publications from the NAVIGATE trial, and a significant balance sheet transaction in which Chairman Richard E. Uihlein converted approximately $105.8 million of principal and accrued interest under five company credit facilities into 34,376,167 shares of common stock effective July 31, 2026, thereby eliminating that debt; the company also disclosed it had $13.2 million of cash and cash equivalents and expects existing resources and an undrawn $10 million credit facility to fund operations and R&D through June 2027, while reporting a Q2 2026 net loss applicable to common stockholders of $9.2 million, or $0.14 per share.

Filing Facts

CIK

1133416

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-032946

Alert Tier

7